| Prev Close | 9.47 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 3.10 / 12.80 |
| Avg Volume | 67.40K |
| Exchange | NASDAQ |
| Shares Outstanding | 6.90M |
| Market Cap | 69.58M |
| EPS | -1.80 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Resubmission of the REMOXY NDA On-Track for Q1 2018
Peer-reviewed Publication Supports On-Going Clinical Development of PTI-125
Pre-NDA Meeting, November 14th for REMOXY™ ER
PTI-125 Is Well-Tolerated in First-in-human Clinical Study
Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.
Provides Funding for FENROCK™, an Abuse-deterrent Pain Patch
Clinical Study Initiation Is Expected Shortly, with Funding by NIH
NIH Grant Will Support Clinical Testing of PTI-125, an Experimental Drug Candidate
PTI-125, an Experimental Drug, Restored Receptor Function and Significantly Improved Working Memory and Spatial Ability in a Transgenic Mouse Model of Alzheimer's Disease
Stock to Trade on a Split-adjusted Basis Beginning May 10, 2017
- Company Will Host Conference Call on Tuesday, March 21st, at 8am Eastern Time -
FDA Meeting Set for February 13, 2017
Here's a technical look at how to trade some of the most active stocks on the market right now.
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
These low-dollar biotech stocks are making big moves Monday -- in opposite directions.
